ClinicalTrials.gg
CompletedNCT00269399Updated Oct 14, 2019Results posted

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

A Phase 3 interventional study of Rifaximin (Xifaxan) and Vancomycin in Clostridium Infections and Diarrhea, sponsored by Bausch Health Americas, Inc.. Completed at 63 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-14.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies in Clostridium Infections with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Clostridium Infections · United States.

Enrollment
18th of 102
237 · median 57
Started
2005
with 2 others
Phase 3
16 of 121
1 open now
Registered
4th of 121
by date

Among the 121 studies in Clostridium Infections with a site in United States, this one is the 18th largest by enrollment of the 102 interventional ones that give a count, is one of 3 that started in 2005, is one of 16 in phase 3, and was the 4th registered.

Clostridium Infections

251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.

Browse Clostridium Infections studies →

Open to participants now

16 of the 121 studies in Clostridium Infections with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Clostridium Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).

Read the detailed description

Clostridium difficile is a bacterium that proliferates when normal colonic flora have been altered, most commonly due to antibiotic use. Clostridium difficile is non-invasive and localized to the lumen of the colon. Once established, it produces 2 potent toxins, A and B. The principal reservoir for Clostridium difficile is the hospital environment, with the risk of acquiring Clostridium difficile increasing in direct proportion to the length of hospital stay.

Patients with CDAD typically present with profuse watery or mucoid diarrhea and cramping abdominal pain. Additional symptoms include fever, nausea, anorexia, malaise, and bloody stool. More severe cases may be complicated by dehydration, electrolyte disturbances, ileus, and peritonitis. Systemic manifestations may include prerenal azotemia, sepsis syndrome, and toxic colitis. White blood cell counts (WBCs) also may be markedly elevated with a shift to immature forms. Extreme presentation of fulminant colitis may require a colectomy and even result in death. Symptoms of CDAD may begin a few days after initiation of antibiotic therapy or up to 8 weeks after its discontinuation.

03

Conditions studied

  • Clostridium Infections
  • Diarrhea

Keywords

  • Clostridium difficile-associated Diarrhea (CDAD)
  • CDAD
  • C diff
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is 18 years of age or older, has acute diarrhea and at least 1 other sign of enteric infection present, such as fever, nausea/loss of appetite, vomiting, severe abdominal pain or discomfort.
  • Subject has a positive Clostridium difficile stool toxin assay at screening

Exclusion criteria

Exclusion Criteria:

  • Subject has had a previous episode of clinically diagnosed Clostridium difficile within the past 6 months.
  • Subject has chronic diseases associated with diarrhea (e.g., inflammatory bowel disease or diarrhea predominant irritable bowel syndrome [DIBS])
  • Subject has had any therapy with any agent administered for the treatment of Clostridium difficile prior to randomization.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
237 participants (actual)

Study arms

  • Experimental
    Rifaximin Treatment Arm

    rifaximin 400mg taken 3 times a day

    Drug: Rifaximin (Xifaxan)

  • Active comparator
    Vancomycin Comparator Arm

    vancomycin 125mg taken 4 times a day

    Drug: Vancomycin

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.

    Resolution or improvement of baseline signs and symptoms was assessed as * Absence of severe abdominal pain for 2 consecutive days at the test of cure (TOC) Visit (Day 14 +/-1); * Absence of fever (\< 38°C/100.4°F) for 2 consecutive days at the TOC Visit; and * 3 unformed (loose or watery) stools per day for at least 48 hours that was sustained through the TOC Visit.

    Time frame: 14 days

Secondary outcomes

  1. Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success

    Recurrence of CDAD was defined as diarrhea and a positive Clostridium difficile stool toxin assay that occurs after initial clinical success.

    Time frame: 42 days

07

Results

Posted Oct 1, 2019

Participant flow

Participant flow — Overall Study
MilestoneRifaximin Treatment ArmVancomycin Comparator Arm
Started119118
Completed7891
Not completed4127
Withdrew: Lack of efficacy2710
Withdrew: Adverse event104
Withdrew: Withdrawal by subject25
Withdrew: Negative lab result for c. difficile23
Withdrew: Other04
Withdrew: Development of exclusion criteria01

Outcome measures

PrimaryProportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.

Resolution or improvement of baseline signs and symptoms was assessed as * Absence of severe abdominal pain for 2 consecutive days at the test of cure (TOC) Visit (Day 14 +/-1); * Absence of fever (\< 38°C/100.4°F) for 2 consecutive days at the TOC Visit; and * 3 unformed (loose or watery) stools per day for at least 48 hours that was sustained through the TOC Visit.

Time frame:
14 days
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.
ParticipantsRifaximin Treatment ArmVancomycin Comparator Arm
Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.6773
SecondaryProportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success

Recurrence of CDAD was defined as diarrhea and a positive Clostridium difficile stool toxin assay that occurs after initial clinical success.

Time frame:
42 days
Reported as:
Count of participants · Participants
Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success
ParticipantsRifaximin Treatment ArmVancomycin Comparator Arm
Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success6163

Adverse events

Collected over 42 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifaximin Treatment Arm—28/120 (23.3%)6/120 (5%)
Vancomycin Comparator Arm—14/116 (12.1%)2/116 (1.7%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventRifaximin Treatment ArmVancomycin Comparator Arm
DehydrationMetabolism and nutrition disorders3/1204/116
Abdominal painGastrointestinal disorders4/1200/116
DiarrheaGastrointestinal disorders3/1203/116
Renal failure acuteRenal and urinary disorders3/1202/116
HypotensionVascular disorders3/1202/116
PneumoniaInfections and infestations0/1202/116
Mental status changesPsychiatric disorders0/1202/116
Clostridial infectionInfections and infestations2/1201/116
Clostridium colitisInfections and infestations2/1200/116
AnemiaBlood and lymphatic system disorders1/1201/116
Most frequent other events
Most frequent other events
EventRifaximin Treatment ArmVancomycin Comparator Arm
InsomniaPsychiatric disorders6/1202/116

Baseline characteristics

Modified Intent-to-Treat (MITT) population included all randomized subjects who had acute diarrhea and with a positive C. difficile stool toxin assay within ± 48 hours of screening and received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Rifaximin Treatment ArmVancomycin Comparator ArmTotal
Mean58.9 ± 16.2260.0 ± 18.0859.5 ± 17.14
Sex: Female, Male
Sex: Female, Male(Participants)Rifaximin Treatment ArmVancomycin Comparator ArmTotal
Female7467141
Male434891
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rifaximin Treatment ArmVancomycin Comparator ArmTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American141226
White103102205
More than one race000
Unknown or Not Reported000
08

Study locations

63 sites
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Inland Empire Digestive & Liver Diseases
    Redlands, California 92373, United States
  • Gastroenterology of the Rockies
    Longmont, Colorado 80501, United States
  • Connecticut Gastroenterology Institute
    Bristol, Connecticut 06010-0977, United States
  • The George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • Halifax Medical Center
    Daytona Beach, Florida 32114, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Webster Surgical Center LLC
    Tallahassee, Florida 32308, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Southeast Regional Research Group
    Columbus, Georgia 31904, United States
  • Sky Blue, M.D.
    Boise, Idaho 83712, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Gastroenterology, Ltd.
    Peoria, Illinois 61602, United States
  • Springfield Clinic
    Springfield, Illinois 62701, United States
  • Memorial Medical Center
    Springfield, Illinois 62702, United States
  • Carle Clinic Association NCW5
    Urbana, Illinois 61801, United States
  • Iowa Digestive Disease Center, PC
    Des Moines, Iowa 50312-5300, United States
  • GI Specialists
    Olathe, Kansas 66061, United States
  • Gastrointestinal Associates
    Overland Park, Kansas 66212, United States
  • Kansas Medical Clinic
    Topeka, Kansas 66606, United States
  • Baltimore VA Medical Center
    Baltimore, Maryland 21201, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Center for Clinical Research at Washington County Hospital
    Hagerstown, Maryland 21740, United States
  • Shah Associates
    Prince Frederick, Maryland 20678, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Arnold Markowitz, MD, PC
    Keego Harbor, Michigan 48320, United States
  • Newland Medical Association
    Southfield, Michigan 48075, United States
  • St. Mary's/Duluth Clinic Health System
    Duluth, Minnesota 55805, United States
  • Minneapolis VAMC
    Minneapolis, Minnesota 55417, United States
  • Infectious Disease - Minneapolis Ltd.
    Minneapolis, Minnesota 55422, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Digestive Health Specialists, PA
    Tupelo, Mississippi 38801, United States
  • Deaconess Billings Clinic Research
    Billings, Montana 59101, United States
  • Infectious Diseases Associates, PC
    Omaha, Nebraska 68114, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Drs. Scherl, Chessler, Zingler, Spinnel and Meininger
    Fort Lee, New Jersey 07024, United States
  • Marlboro Gastroenterology PC
    Manalapan, New Jersey 07726, United States
  • St. Michael's Medical Center
    Newark, New Jersey 07102, United States
  • Institute for Clinical Research (ICR) at Holy Name Hospital
    Teaneck, New Jersey 07666, United States
  • The Gastroenterology Group of South Jersey
    Vineland, New Jersey 08360, United States
  • Brookdale University Hospital and Medical Center
    Brooklyn, New York 11212, United States
  • AMS Clinical Research
    Elmira, New York 14905, United States
  • North Shore Hepatology
    Manhasset, New York 11030, United States
  • Weill Medical College
    New York, New York 10021, United States
  • University of Rochester School of Medicine
    Rochester, New York 14642, United States
  • New York Medical College/Westchester Medical Center
    Valhalla, New York 10595, United States
  • East Carolina Gastroenterology, PA
    Jacksonville, North Carolina 28546, United States
  • Southern Gastroenterology Associates
    New Bern, North Carolina 28562, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0595, United States
  • Regional Infectious Diseases - Infusion Center
    Lima, Ohio 45801, United States
  • Lima Memorial Health System
    Lima, Ohio 45804, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • Drexel University College of Medicine
    Philadelphia, Pennsylvania 19107, United States
  • RPS Infectious Diseases
    West Reading, Pennsylvania 19611, United States
  • University Gastroenterology
    Providence, Rhode Island 02905, United States
  • Digestive Disease Associates of Dallas
    Dallas, Texas 75231, United States
  • Michael E. DeBakey VA Medical Center
    Houston, Texas 77030, United States
  • University of Texas Health Sciences Center
    Houston, Texas 77030, United States
  • Infectious Disease Associates of Central Virginia
    Lynchburg, Virginia 24501, United States
  • North Pacific Clinical Research
    Redmond, Washington 98052, United States
  • Associated Physicians, LLP
    Madison, Wisconsin 53705, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 10 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2005
First posted
Dec 23, 2005
Start
Dec 2005
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Oct 1, 2019
Last update
Oct 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00269399
Responsible party
Sponsor
First posted
Dec 23, 2005
Start date
Dec 2005
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Oct 1, 2019
Last update
Oct 14, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion